US FDA Reopens Door For CBD Safety Data, But NPA Says Window Closing For Setting Safe Level

As it recently told Congress it would, FDA reopens docket on “Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived,. "Reopening the comment period will do nothing to protect public health when the FDA is already sitting on a ticking time bomb," says NPA head Daniel Fabricant.